# Rivaroxaban for Antiphospholipid Antibody Syndrome

> **NCT02116036** · PHASE4 · COMPLETED · sponsor: **St. Joseph's Healthcare Hamilton** · enrollment: 81 (actual)

## Conditions studied

- Antiphospholipid Antibody Syndrome

## Interventions

- **DRUG:** Rivaroxaban

## Key facts

- **NCT ID:** NCT02116036
- **Lead sponsor:** St. Joseph's Healthcare Hamilton
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2017-09-30
- **Final completion:** 2017-09-30
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2017-10-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02116036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02116036, "Rivaroxaban for Antiphospholipid Antibody Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02116036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*